Skip to main content
FENC
NASDAQ Life Sciences

Fennec Pharmaceuticals Announces New Investigator-Sponsored Study for PEDMARK® in Adult Cancers

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$6.32
Mkt Cap
$217.883M
52W Low
$4.68
52W High
$9.92
52W Position info
35% above low
Off High info
36% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

FENC sits 35% above its 52-week low of $4.68.

Summary

Fennec Pharmaceuticals announced a new investigator-sponsored study for PEDMARK® to evaluate its use in AYA and adult patients with head and neck and testicular cancers, aiming to expand the drug's market and clinical evidence.


Key Events · Product Development and Regulatory · FENC

  • New Investigator-Sponsored Study Initiated

    The University of Arizona Cancer Center has initiated a Phase I/II open-label trial to evaluate PEDMARK® (sodium thiosulfate injection) as an otoprotectant in adolescent and young adult (AYA) and adult patients with head and neck and testicular cancers receiving cisplatin chemotherapy.

  • Expansion of PEDMARK®'s Potential Use

    This study aims to build real-world evidence and expand the understanding of PEDMARK®'s benefits beyond its current FDA-approved indication for pediatric patients, potentially supporting broader clinical adoption and future label expansion for AYA and adult cancer patients.

  • Ongoing Research Efforts

    This new study follows the initiation of two other institution-led clinical studies announced in March 2026 and December 2025, demonstrating Fennec's commitment to supporting independent research for PEDMARK®.


Analysis · FENC · Life Sciences

Fennec Pharmaceuticals announced the initiation of a new investigator-sponsored study for its drug, PEDMARK®, at the University of Arizona Cancer Center. This study will evaluate PEDMARK® in adolescent and young adult (AYA) and adult patients with head and neck and testicular cancers receiving cisplatin. This is a positive development as it expands the clinical evidence and potential market for PEDMARK® beyond its current pediatric indication, aligning with the company's strategy to support broader clinical adoption and potential label expansion. The company has recently announced other similar institution-led studies, indicating a concerted effort to build real-world data for its key product.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, FENC was trading at $6.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $217.9M. The 52-week trading range was $4.68 to $9.92. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

FENC - Latest Insights

FENC
Nov 12, 2026, 4:05 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $10.90
Real-time Price: $11.62 info
Change: +$0.720 (+7%) info
Market Cap: $410.245M info
FENC
Nov 12, 2026, 6:06 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $10.64
Real-time Price: $11.62 info
Change: +$0.980 (+9%) info
Market Cap: $410.245M info
FENC
Sep 17, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $10.78
Real-time Price: $11.62 info
Change: +$0.840 (+8%) info
Market Cap: $410.245M info
FENC
Sep 17, 2026, 7:30 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $10.55
Real-time Price: $11.62 info
Change: +$1.07 (+10%) info
Market Cap: $410.245M info
FENC
Aug 13, 2026, 4:03 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $12.06
Real-time Price: $11.62 info
Change: -$0.440 (-4%) info
Market Cap: $410.245M info